eli lilly stock soars following data suggesting its alzheimer's drug can slow illness
Published 1 year ago • 1.4K plays • Length 2:32Download video MP4
Download video MP3
Similar videos
-
3:04
eli lilly's alzheimer's drug slows cognitive decline: study
-
4:38
eli lilly closer to securing fda approval for alzheimer's drug
-
1:47
promising data from eli lilly shows a significant slowdown in the pace of alzheimer's
-
6:33
eli lilly stock gains on weight loss drug that cuts type 2 diabetes risk by 94%
-
2:34
fda rejects eli lilly’s accelerated approval application for alzheimer’s drug
-
3:39
what eli lilly, novo nordisk earnings show about glp-1 sales
-
7:33
why eli lilly is a top glp-1 stock: roundhill ceo
-
6:05
eli lilly ceo david ricks on q2 results: seeing unbelievable demand for zepbound and mounjaro
-
4:19
eli lilly is a 'great destination for investors', says deutsche bank's james shin after upgrade
-
5:53
eli lilly and novo nordisk will remain leaders in the weight-loss drug market: mizuho's jared holz
-
2:38
eli lilly suffers setback in alzheimer’s treatment plans
-
4:40
eli lilly ceo discusses fda's approval of biogen's new alzheimer's drug
-
4:22
fda approves a new alzheimer's drug from eli lilly
-
4:03
eli lilly ceo: alzheimer's drug trial shows slowed disease progression by 40-60% in early patients
-
4:30
eli lilly ceo on fda approval pathway for alzheimer's drugs
-
1:21
fda approves eli lilly's alzheimer's drug kisunla
-
1:25
lilly drug slows alzheimer's progression by 35% in trial
-
11:07
eli lilly ceo talks expanding innovation past obesity drugs
-
3:13
eli lilly ceo: we see a path to an alzheimer's disease-modifying drug
-
3:46
eli lilly ceo david ricks on positive alzheimer's drug trial data
-
1:26
eli lilly weight loss drug for type-2 diabetes approved by the fda
-
6:48
eli lilly's alzheimer's drug slowed cognitive decline in phase 3 study